澳大利亚医院发起的出院后药物审查:关于实施障碍和促进因素的专家意见

IF 1 Q4 PHARMACOLOGY & PHARMACY
Manya Angley BPharm, PhD, AACPA, AdvPracPharm, FSHP, FPS, Deirdre Criddle BPharm, GradDipPharm, AACPA, AdvPracPharm, FPS, MSHP, MRPharmS, Deborah Rigby BPharm, GradDipClinPharm, AdvPracPharm, AACPA, FPS, FSHPA, FACP, FASCP, FAICD, Rohan A. Elliott BPharm, BPharmSc (Hons), MClinPharm, FSHP, PhD, Katie Phillips BPharm (Hons), Grad Cert Pharmacy Practice, AACPA, MSHP, Jonathan Penm BPharm (Hons), PhD, GradCert (Higher Ed), FFIP, FSHP, FHEA, Janet K. Sluggett BPharm (Hons), PhD, GradDipClinEpid, AACPA, FSHP, GAICD, Joy Gailer BPharm, DipHospPharm, BCPS, AdvPracPharm, FPS, MSHP, Horst Thiele DipPharm, MSHP, Amy T. Page PhD, BHealth Sci, BPharm, Grad Dip Biostatistics, Grad Cert Health Prof Ed, Grad Cert Pharm Pract, MClinPharm, AACPA, AdvPracPharm, FPS, Carly Pauw BPharm, MSHP, Sarah Gillespie BPharm, AACPA, MSHP, MPS, Sepehr Shakib MBBS, PhD, FRACP, Jerry Yik BPharm MPubPol
{"title":"澳大利亚医院发起的出院后药物审查:关于实施障碍和促进因素的专家意见","authors":"Manya Angley BPharm, PhD, AACPA, AdvPracPharm, FSHP, FPS,&nbsp;Deirdre Criddle BPharm, GradDipPharm, AACPA, AdvPracPharm, FPS, MSHP, MRPharmS,&nbsp;Deborah Rigby BPharm, GradDipClinPharm, AdvPracPharm, AACPA, FPS, FSHPA, FACP, FASCP, FAICD,&nbsp;Rohan A. Elliott BPharm, BPharmSc (Hons), MClinPharm, FSHP, PhD,&nbsp;Katie Phillips BPharm (Hons), Grad Cert Pharmacy Practice, AACPA, MSHP,&nbsp;Jonathan Penm BPharm (Hons), PhD, GradCert (Higher Ed), FFIP, FSHP, FHEA,&nbsp;Janet K. Sluggett BPharm (Hons), PhD, GradDipClinEpid, AACPA, FSHP, GAICD,&nbsp;Joy Gailer BPharm, DipHospPharm, BCPS, AdvPracPharm, FPS, MSHP,&nbsp;Horst Thiele DipPharm, MSHP,&nbsp;Amy T. Page PhD, BHealth Sci, BPharm, Grad Dip Biostatistics, Grad Cert Health Prof Ed, Grad Cert Pharm Pract, MClinPharm, AACPA, AdvPracPharm, FPS,&nbsp;Carly Pauw BPharm, MSHP,&nbsp;Sarah Gillespie BPharm, AACPA, MSHP, MPS,&nbsp;Sepehr Shakib MBBS, PhD, FRACP,&nbsp;Jerry Yik BPharm MPubPol","doi":"10.1002/jppr.1832","DOIUrl":null,"url":null,"abstract":"<p>Medication-related harm can occur during transitions of care. Revised Home Medicines Review (HMR) and Residential Medication Management Review (RMMR) program rules were published in April 2020 which allowed provision for some hospital medical practitioners to refer at-risk patients for medication review. In turn, the Society of Hospital Pharmacists of Australia's (SHPA's) Transitions of Care and Primary Care Leadership Committee developed a framework to support hospitals facilitating Hospital-Initiated Medication Reviews (HIMRs) via three pathways: HMR, RMMR, and Hospital Outreach Medication Review. Following the compilation of draft barriers and enablers to implementation of the SHPA HIMR framework, refinement occurred after broad consultation with hospital- and primary care-based pharmacists with transitions of care experience. The finalised list of barriers and enablers can inform broadscale implementation of the SHPA HIMR framework to reduce medication-related harm when high-risk patients transition from hospital to primary care and aged care.</p>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":null,"pages":null},"PeriodicalIF":1.0000,"publicationDate":"2022-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Hospital-initiated post-discharge medication reviews in Australia: expert opinion on the barriers and enablers to implementation\",\"authors\":\"Manya Angley BPharm, PhD, AACPA, AdvPracPharm, FSHP, FPS,&nbsp;Deirdre Criddle BPharm, GradDipPharm, AACPA, AdvPracPharm, FPS, MSHP, MRPharmS,&nbsp;Deborah Rigby BPharm, GradDipClinPharm, AdvPracPharm, AACPA, FPS, FSHPA, FACP, FASCP, FAICD,&nbsp;Rohan A. Elliott BPharm, BPharmSc (Hons), MClinPharm, FSHP, PhD,&nbsp;Katie Phillips BPharm (Hons), Grad Cert Pharmacy Practice, AACPA, MSHP,&nbsp;Jonathan Penm BPharm (Hons), PhD, GradCert (Higher Ed), FFIP, FSHP, FHEA,&nbsp;Janet K. Sluggett BPharm (Hons), PhD, GradDipClinEpid, AACPA, FSHP, GAICD,&nbsp;Joy Gailer BPharm, DipHospPharm, BCPS, AdvPracPharm, FPS, MSHP,&nbsp;Horst Thiele DipPharm, MSHP,&nbsp;Amy T. Page PhD, BHealth Sci, BPharm, Grad Dip Biostatistics, Grad Cert Health Prof Ed, Grad Cert Pharm Pract, MClinPharm, AACPA, AdvPracPharm, FPS,&nbsp;Carly Pauw BPharm, MSHP,&nbsp;Sarah Gillespie BPharm, AACPA, MSHP, MPS,&nbsp;Sepehr Shakib MBBS, PhD, FRACP,&nbsp;Jerry Yik BPharm MPubPol\",\"doi\":\"10.1002/jppr.1832\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Medication-related harm can occur during transitions of care. Revised Home Medicines Review (HMR) and Residential Medication Management Review (RMMR) program rules were published in April 2020 which allowed provision for some hospital medical practitioners to refer at-risk patients for medication review. In turn, the Society of Hospital Pharmacists of Australia's (SHPA's) Transitions of Care and Primary Care Leadership Committee developed a framework to support hospitals facilitating Hospital-Initiated Medication Reviews (HIMRs) via three pathways: HMR, RMMR, and Hospital Outreach Medication Review. Following the compilation of draft barriers and enablers to implementation of the SHPA HIMR framework, refinement occurred after broad consultation with hospital- and primary care-based pharmacists with transitions of care experience. The finalised list of barriers and enablers can inform broadscale implementation of the SHPA HIMR framework to reduce medication-related harm when high-risk patients transition from hospital to primary care and aged care.</p>\",\"PeriodicalId\":16795,\"journal\":{\"name\":\"Journal of Pharmacy Practice and Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2022-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy Practice and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jppr.1832\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Practice and Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jppr.1832","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 2

摘要

与药物有关的伤害可能发生在护理的过渡阶段。修订后的家庭药物审查(HMR)和住院药物管理审查(RMMR)计划规则于2020年4月发布,允许一些医院医生推荐有风险的患者进行药物审查。反过来,澳大利亚医院药剂师协会(SHPA)的护理过渡和初级保健领导委员会制定了一个框架,以支持医院通过三种途径促进医院发起的药物审查(HIMRs): HMR, RMMR和医院外展药物审查。在编制了实施SHPA HIMR框架的障碍和促进因素草案之后,在与医院和初级保健的药剂师进行了广泛的咨询后,对其进行了改进。最终确定的障碍和促进因素清单可以为SHPA HIMR框架的广泛实施提供信息,以减少高风险患者从医院转向初级保健和老年保健时的药物相关伤害。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Hospital-initiated post-discharge medication reviews in Australia: expert opinion on the barriers and enablers to implementation

Medication-related harm can occur during transitions of care. Revised Home Medicines Review (HMR) and Residential Medication Management Review (RMMR) program rules were published in April 2020 which allowed provision for some hospital medical practitioners to refer at-risk patients for medication review. In turn, the Society of Hospital Pharmacists of Australia's (SHPA's) Transitions of Care and Primary Care Leadership Committee developed a framework to support hospitals facilitating Hospital-Initiated Medication Reviews (HIMRs) via three pathways: HMR, RMMR, and Hospital Outreach Medication Review. Following the compilation of draft barriers and enablers to implementation of the SHPA HIMR framework, refinement occurred after broad consultation with hospital- and primary care-based pharmacists with transitions of care experience. The finalised list of barriers and enablers can inform broadscale implementation of the SHPA HIMR framework to reduce medication-related harm when high-risk patients transition from hospital to primary care and aged care.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Pharmacy Practice and Research
Journal of Pharmacy Practice and Research Health Professions-Pharmacy
CiteScore
1.60
自引率
9.50%
发文量
68
期刊介绍: The purpose of this document is to describe the structure, function and operations of the Journal of Pharmacy Practice and Research, the official journal of the Society of Hospital Pharmacists of Australia (SHPA). It is owned, published by and copyrighted to SHPA. However, the Journal is to some extent unique within SHPA in that it ‘…has complete editorial freedom in terms of content and is not under the direction of the Society or its Council in such matters…’. This statement, originally based on a Role Statement for the Editor-in-Chief 1993, is also based on the definition of ‘editorial independence’ from the World Association of Medical Editors and adopted by the International Committee of Medical Journal Editors.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信